Gimsilumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, gimsilumab targets, binds to and neutralizes GM-CSF. This prevents the binding of GM-CSF to its targeted inflammatory cells, and prevents proliferation and activation of various immune cells. This prevents the release of cytokines and B- and T-cell-mediated immune responses. GM-CSF, a monomeric glycoprotein functioning as a cytokine, promotes the proliferation and activation of macrophages and neutrophils. GM-CSF levels are elevated in certain immune-mediated diseases. It increases the production of pro-inflammatory mediators, such as cytokines, chemokines and proteases.

**Synonyms:** - GIMSILUMAB - Immunoglobulin G1, Anti-(Human Granulocyte-Macrophage Colony-Stimulating Factor) (Human Monoclonal Morab-022 Heavy Chain), Disulfide with Human Monoclonal Morab-022 Kappa-Chain, Dimer - MORAB022 - MORAb-022